Login to Your Account


Genentech’s onartuzumab fails in phase III trial for non-small-cell lung cancer

By Marie Powers
Staff Writer

Tuesday, March 4, 2014
Roche AG unit Genentech Inc. said it was halting the phase III METLung study of onartuzumab, or Metmab, in combination with Tarceva (erlotinib, Roche and Astellas Pharma Inc.) in MET-positive, advanced non-small-cell lung cancer (NSCLC) on the recommendation of an independent data monitoring committee after a planned interim analysis showed the drug did not meet its primary endpoint of overall survival (OS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription